autologous AXL-targeted CAR-T cells CCT301-38

{
  "id": "MLC-T-ONC-011504",
  "term": "autologous AXL-targeted CAR-T cells CCT301-38",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of genetically modified autologous T lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.",
  "synonyms": [
    "autologous CAR-T cells targeting AXL CCT301-38",
    "CCT30138 CAR-T cells",
    "autologous anti-AXL CAR-T Cells CCT30138"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-axl-targeted-car-t-cells-cct301-38/"
}